
Browsing restrictions can be lifted for a fee.
-2.51%
Heartsciences inc.
0.05%
Avg of Sector
-0.31%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Heartsciences inc. (HSCS) covers the period of 2026Q2 and was published on 2025/10/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating HSCS's short-term business performance and financial health. For the latest updates on HSCS's earnings releases, visit this page regularly.
According to the latest financial report, Heartsciences inc. (HSCS) reported an Operating Profit of -2.07M with an Operating Margin of -85,713.23% this period, representing a decline of 4.45% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Heartsciences inc. (HSCS) announced revenue of 2.42K, with a Year-Over-Year growth rate of 0%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Heartsciences inc. (HSCS) had total debt of 876.24K, with a debt ratio of 0.15. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Heartsciences inc. (HSCS) held Total Cash and Cash Equivalents of 1.95M, accounting for 0.33 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Heartsciences inc. (HSCS) did not achieve the “three margins increasing” benchmark, with a gross margin of 58.3%%, operating margin of -85,713.23%%, and net margin of -97,179.4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess HSCS's profit trajectory and future growth potential.
According to the past four quarterly reports, Heartsciences inc. (HSCS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.85. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Heartsciences inc. (HSCS)'s Free Cash Flow (FCF) for the period is -2.35M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 7.34% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
The latest valuation data shows Heartsciences inc. (HSCS) has a Price-To-Earnings (PE) ratio of -0.87 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.